Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
NCT02495233 · Astellas Pharma Global Development, Inc. · PHASE1/PHASE2 · terminated · last registry update 2024-11-27 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated due to adverse events related to the combination therapy” | Open Targets' class: safety sideeffects | Registry record, Astellas Pharma Global Development, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FLT3 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-11-10Results posted on the registry: Boehringer Ingelheim, BI 836880 + Ezabenlimab (NCT03468426)
- 2025-09-23Also stopped (terminated): Jiangsu HengRui Medicine Co., Ltd., Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;Placebo (NCT04619433)
- 2024-08-09Also stopped (withdrawn): Jiangsu Province Nanjing Brain Hospital, Adebelimumab+Famitinib + FOLFIRI+Ariely (NCT06332300)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision